Compare
OS Therapies Inc vs Serina Therapeutics, Inc. vs CV Sciences, Inc. vs Cannapharmarx, Inc.
| Latest fiscal year | OS Therapies Inc OSTX | Serina Therapeutics, Inc. SER | CV Sciences, Inc. CVSI | Cannapharmarx, Inc. CPMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $130.0K | $13.79M | $1.36M |
| Revenue growth (YoY) | n/a | +132.1% | -12.2% | +66.1% |
| Gross margin | n/a | n/a | 49.0% | -153.1% |
| Operating margin | n/a | n/m | -3.4% | -245.8% |
| Net margin | n/a | n/m | -6.9% | -817.2% |
| Net income | -$28.75M | -$19.18M | -$958.0K | -$11.13M |
| EPS (Diluted) | -$0.98 | -$1.91 | -$0.01 | -$0.02 |
| Operating cash flow | -$14.24M | -$17.95M | -$407.0K | -$789.1K |
| Free cash flow | -$14.70M | -$18.01M | -$516.0K | -$794.6K |
| Cash & equivalents | n/a | $3.06M | n/a | $1.8K |
| Total assets | $6.84M | $6.95M | $6.96M | $7.02M |
| Total liabilities | $11.86M | $6.99M | $5.49M | $37.17M |
| Shareholders' equity | -$6.10M | -$37.0K | $1.47M | -$30.15M |
| Return on year-end equity | n/a | n/a | -65.3% | n/a |
| Shares outstanding | 37.11M | 10.77M | 184.26M | 662.50M |
Revenue, most recent five fiscal years
| Fiscal year | OS Therapies Inc | Serina Therapeutics, Inc. | CV Sciences, Inc. | Cannapharmarx, Inc. |
|---|---|---|---|---|
| Latest | n/a | $130.0K Ended 2025-12-31 | $13.79M Ended 2025-12-31 | $1.36M Ended 2025-12-31 |
| 1 year earlier | n/a | $56.0K Ended 2024-12-31 | $15.71M Ended 2024-12-31 | $820.1K Ended 2024-12-31 |
| 2 years earlier | n/a | $3.15M Ended 2023-12-31 | $16.00M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $34.0K Ended 2022-12-31 | $16.20M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $144.0K Ended 2021-12-31 | $20.05M Ended 2021-12-31 | $0 Ended 2021-12-31 |